Posted by Michael Wonder on 02 Nov 2021
ANI Pharmaceuticals announces FDA approval of purified cortrophin gel for multiple indications including multiple sclerosis, rheumatoid arthritis and nephrotic syndrome
1 November 2021 - Approval re-introduces much needed patient and physician choice into the U.S. repository corticotropin market.
ANI Pharmaceuticals today announced that the U.S. FDA has approved the Company’s supplemental new drug application for Purified Cortrophin Gel (Repository Corticotropin Injection USP) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis, in addition to excess urinary protein due to nephrotic syndrome.
